Trial Profile
A Retrospective, Observational Study Assessing the Response to Omalizumab Treatment According to Blood Eosinophil Count in Patients with Severe Allergic Asthma (SAA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Acronyms STELLAIR
- 15 Mar 2018 Results assessing safety and efficacy published in the European Respiratory Journal
- 17 Nov 2017 New trial record